# AstraZeneca’s AZD7442 Phase III trial positive in COVID outpatients

- Link: https://www.directorstalkinterviews.com/astrazenecas-azd7442-phase-iii-trial-positive-in-covid-outpatients/4121027183
- Published: 2021-10-11T07:17:47+01:00
- Author: Amilia Stone

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed**
[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
AZD7442, a long acting antibody (LAAB) combination, achieved a statistically significant
reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients
with mild-to-moderate symptomatic COVID-19.

A total of 90% of participants enrolled were from populations at high risk of progression
to severe COVID-19, including those with co-morbidities.

The trial met the primary endpoint, with a dose of 600mg of AZD7442 given by intramuscular(
IM) injection reducing the risk of developing severe COVID-19 or death (from any
cause) by 50% compared to placebo in outpatients who had been symptomatic for seven
days or less. The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in
the placebo arm (37/415). The LAAB was generally well tolerated in the trial.

In a prespecified analysis of participants who received treatment within five days
of symptom onset, AZD7442 reduced the risk of developing severe COVID-19 or death(
from any cause) by 67% compared to placebo, with nine events in the AZD7442 arm (
9/253) and 27 in the placebo arm (27/251).

AZD7442 is the first LAAB with Phase III data to demonstrate benefit in both prophylaxis
and treatment of COVID-19 and is easily administered by IM injection.

> **Hugh Montgomery, Professor of Intensive Care Medicine at University College 
> London, and TACKLE principal investigator, said**: “With continued cases of serious
> COVID-19 infections across the globe, there is a significant need for new therapies
> like AZD7442 that can be used to protect vulnerable populations from getting COVID-
> 19 and can also help prevent progression to severe disease. These positive results
> show that a convenient intramuscular dose of AZD7442 could play an important role
> in helping combat this devastating pandemic.”

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca,
> said**: “These important results for AZD7442, our long-acting antibody combination,
> add to the growing body of evidence for use of this therapy in both prevention
> and treatment of COVID-19. An early intervention with our antibody can give a 
> significant reduction in progression to severe disease, with continued protection
> for more than six months.”

TACKLE included 903 participants in a 1:1 randomisation AZD7442 to placebo. The 
primary analysis was based on 822 participants.

AstraZeneca will be discussing the data with health authorities. On 5 October 2021,
the Company announced that it had submitted a request to the US Food and Drug Administration
for Emergency Use Authorisation for AZD7442 for prophylaxis of COVID-19.

Full results from TACKLE will be submitted for publication in a peer-reviewed medical
journal and presented at a forthcoming medical meeting.

Share on:
